<DOC>
	<DOCNO>NCT02778906</DOCNO>
	<brief_summary>This randomise double-blinded placebo-controlled multi centre study 98 patient ACPA positive arthralgia . The study compose 2 arm 1:1 randomisation baseline : Treatment phase 6 month . Group 1 : Abatacept s.c. 125 mg weekly 6 month vs. Group 2 : Placebo s.c. 6 month . After 6 month group run follow period another 12 month month 18 . Patients develop arthritis treat accord local guideline .</brief_summary>
	<brief_title>Abatacept Reversing Subclinical Inflammation Measured MRI ACPA Positive Arthralgia</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Females male age ≥ 18 year time consent ACPA ( without RF ) Joint pain ( hand , foot , knee , shoulder elbow ) present least 6 week prior inclusion past history Presence synovitis ( synovialitis tenosynovitis ) osteitis MRI dominant hand baseline Women childbearing potential men capable father child must use effective contraception treatment abatacept 14 week last dose abatacept treatment . Must understand voluntarily sign informed consent form include write consent data protection Must able adhere study visit schedule protocol requirement Presence arthritis hand , foot , knee , shoulder elbow joint define swell Current treatment glucocorticoid conventional biologic DMARDs Previous treatment abatacept Investigational study drug within 4 week ( 5 half life , whichever long ) prior randomization Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Any autoimmune inflammatory disease SLE , PSS , MCTD , SpA , Behcet disease , vasculitis autoimmune hepatitis . Any malignancy last 5 year Chronic infection latent TB ( TB adequately treat accord guideline ) hepatitis B C infection Immunocompromised HIVpositive patient Uncontrolled severe concomitant disease Patients young 18 year incapable understand aim , importance consequence study give legal inform consent ( accord § 40 Abs . 4 § 41 Abs . 2 Abs . 3 AMG ) . Pregnant lactating female Patients possibly dependent Principal Investigator Investigator ( e.g . family member ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Abatacept</keyword>
</DOC>